4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally. The company develops Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma. It also out-licenses and partnered drug candidates to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Research context
4SC AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
4SC AG is currently in a long term downtrend where the price is trading 11.9% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 35.3.
4SC AG's total revenue sank by 37.3% to $52K since the same quarter in the previous year.
Its net income has increased by 0.3% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 7.7% to $-3M since the same quarter in the previous year.
Based on the above factors, 4SC AG gets an overall score of 2/5.